Oncology Venture Sweden AB 

Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes 2X-121, a PARP and tankyrase inhibitor in Phase II clinical trials for the treatment of ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin in Phase II clinical trials in breast cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in Hørsholm, Denmark.